1.	Evaluation of [18F]-ML-10 as a PET Imaging Radiotracer for Early Detection of Response of Brain Metastases to Stereotactic Radio Surgery Phase: Phase II Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NST-CA005CTIL, NCT00696943
2.	Evaluation of [18F]-ML-10 as a PET Imaging Radiotracer for Early Detection of Response of Brain Metastases to Whole Brain Radiation Therapy Phase: Phase II Type: Diagnostic Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NST-CA001CTIL, NCT00791063
3.	Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy. Phase: Phase II Type: Diagnostic Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NST-CA004CTIL, NCT00805636
4.	An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation Phase: Phase II Type: Diagnostic Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NST-CA007, NCT01260480
5.	Prospective Study of Preoperative Fludeoxyglucose F 18 Positron Emission Tomography/Computed Tomography Scanning in Assessing Tumor Angiogenesis in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer Phase: No phase specified Type: Biomarker/Laboratory analysis, Diagnostic Status: Active Age: Not specified Sponsor: Other Protocol IDs: UCL-TUMOR-ANGIOGENESIS, UCL-Tumour Angiogenesis, EU-21086, NCT01254591